Denufosol tetrasodium: Phase II started

Inspire began a double-blind, placebo-controlled, U.S. Phase II trial (08-116) to evaluate 60 mg inhaled denufosol given thrice daily in 24 patients ages 2-4 years. Denufosol has Orphan Drug designati...